Product Code: GVR-4-68038-382-9
Automated And Closed Cell Therapy Processing Systems Market Growth & Trends:
The global automated and closed cell therapy processing systems market size is expected to reach USD 4.12 billion by 2030, registering a CAGR of 19.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Market players are making significant investments to introduce an automated process system as a viable strategy to accelerate their cell therapy product development process, thereby driving market growth.
The expansion of GMP manufacturing facilities further supports the implementation of automated processes for commercial operations. In addition, the wide application scope of single-use disposable tubing sets and bags also facilitates automated processing of therapy R&D. Moreover, key entities are undertaking strategies for effective implementation of automation technology in manufacturing labs resulting in lucrative revenue growth.
The rapid growth in the cases of COVID-19 is anticipated to play a vital role in the market growth. The pandemic has led to an increased focus on automation technologies. Moreover, the companies emphasized raising funds with an aim to develop advanced therapies and regenerative medicines to fight against COVID-19. Industry players are also concentrating on the development of new therapies, such as stem cell therapy, natural killer cell therapy, exosomes, and others.
Automated And Closed Cell Therapy Processing Systems Market Report Highlights:
- The separation segment dominated the market and accounted for a share of 31.7% in 2024 and is expected to grow at the fastest CAGR of 20.7% over the forecast period.
- The non stem cell therapy segment accounted for the largest market revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
- The pre-commercial/ R&D scale segment accounted for the largest market revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
- North America automated and closed cell therapy processing systems market held the largest share of 50.1% in 2024 owing to the increasing demand for integrated solutions that streamline the storage, transportation, and processing of cell and gene therapies, enhancing the efficiency of clinical trials and commercialization efforts.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Workflow
- 1.2.2. Type
- 1.2.3. Scale
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Automated and Closed Cell Therapy Processing Systems Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
Chapter 4. Automated and Closed Cell Therapy Processing Systems Market: Workflow Business Analysis
- 4.1. Workflow Market Share, 2024 & 2030
- 4.2. Workflow Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
- 4.4. Separation
- 4.4.1. Separation market, 2018 - 2030 (USD Million)
- 4.5. Expansion
- 4.5.1. Expansion market, 2018 - 2030 (USD Million)
- 4.6. Apheresis
- 4.6.1. Apheresis market, 2018 - 2030 (USD Million)
- 4.7. Fill- Finish
- 4.7.1. Fill- Finish market, 2018 - 2030 (USD Million)
- 4.8. Cryopreservation
- 4.8.1. Cryopreservation market, 2018 - 2030 (USD Million)
- 4.9. Others
- 4.9.1. Others market, 2018 - 2030 (USD Million)
Chapter 5. Automated and Closed Cell Therapy Processing Systems Market: Type Business Analysis
- 5.1. Type Market Share, 2024 & 2030
- 5.2. Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 5.4. Stem Cell Therapy
- 5.4.1. Stem cell therapy market, 2018 - 2030 (USD Million)
- 5.5. Non Stem Cell Therapy
- 5.5.1. Non stem cell therapy market, 2018 - 2030 (USD Million)
Chapter 6. Automated and Closed Cell Therapy Processing Systems Market: Scale Business Analysis
- 6.1. Scale Market Share, 2024 & 2030
- 6.2. Scale Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Scale, 2018 to 2030 (USD Million)
- 6.4. Pre-Commercial/ R&D Scale
- 6.4.1. Pre-commercial/ R&D scale market, 2018 - 2030 (USD Million)
- 6.5. Commercial Scale
- 6.5.1. Commercial scale market, 2018 - 2030 (USD Million)
Chapter 7. Automated and Closed Cell Therapy Processing Systems Market: Country Estimates & Trend Analysis by Workflow, Type and Scale
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key country dynamic
- 7.4.2.2. Regulatory framework
- 7.4.2.3. Competitive insights
- 7.4.2.4. U.S. automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key country dynamic
- 7.4.3.2. Regulatory framework
- 7.4.3.3. Competitive insights
- 7.4.3.4. Canada automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key country dynamic
- 7.4.4.2. Regulatory framework
- 7.4.4.3. Competitive insights
- 7.4.4.4. Mexico automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key country dynamic
- 7.5.2.2. Regulatory framework
- 7.5.2.3. Competitive insights
- 7.5.2.4. UK automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key country dynamic
- 7.5.3.2. Regulatory framework
- 7.5.3.3. Competitive insights
- 7.5.3.4. Germany automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key country dynamic
- 7.5.4.2. Regulatory framework
- 7.5.4.3. Competitive insights
- 7.5.4.4. France automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key country dynamic
- 7.5.5.2. Regulatory framework
- 7.5.5.3. Competitive insights
- 7.5.5.4. Italy automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key country dynamic
- 7.5.6.2. Regulatory framework
- 7.5.6.3. Competitive insights
- 7.5.6.4. Spain automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key country dynamic
- 7.5.7.2. Regulatory framework
- 7.5.7.3. Competitive insights
- 7.5.7.4. Denmark automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key country dynamic
- 7.5.8.2. Regulatory framework
- 7.5.8.3. Competitive insights
- 7.5.8.4. Sweden automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key country dynamic
- 7.5.9.2. Regulatory framework
- 7.5.9.3. Competitive insights
- 7.5.9.4. Norway automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key country dynamic
- 7.6.2.2. Regulatory framework
- 7.6.2.3. Competitive insights
- 7.6.2.4. Japan automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key country dynamic
- 7.6.3.2. Regulatory framework
- 7.6.3.3. Competitive insights
- 7.6.3.4. China automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key country dynamic
- 7.6.4.2. Regulatory framework
- 7.6.4.3. Competitive insights
- 7.6.4.4. India automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key country dynamic
- 7.6.5.2. Regulatory framework
- 7.6.5.3. Competitive insights
- 7.6.5.4. Australia automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamic
- 7.6.6.2. Regulatory framework
- 7.6.6.3. Competitive insights
- 7.6.6.4. Thailand automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.7. South Korea
- 7.6.7.1. Key country dynamic
- 7.6.7.2. Regulatory framework
- 7.6.7.3. Competitive insights
- 7.6.7.4. South Korea automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key country dynamic
- 7.7.2.2. Regulatory framework
- 7.7.2.3. Competitive insights
- 7.7.2.4. Brazil automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key country dynamic
- 7.7.3.2. Regulatory framework
- 7.7.3.3. Competitive insights
- 7.7.3.4. Argentina automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. MEA automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key country dynamic
- 7.8.2.2. Regulatory framework
- 7.8.2.3. Competitive insights
- 7.8.2.4. South Africa automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key country dynamic
- 7.8.3.2. Regulatory framework
- 7.8.3.3. Competitive insights
- 7.8.3.4. Saudi Arabia automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key country dynamic
- 7.8.4.2. Regulatory framework
- 7.8.4.3. Competitive insights
- 7.8.4.4. UAE automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key country dynamic
- 7.8.5.2. Regulatory framework
- 7.8.5.3. Competitive insights
- 7.8.5.4. Kuwait automated and closed cell therapy processing systems market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Miltenyi Biotec
- 8.5.1.1. Overview
- 8.5.1.2. Financial performance
- 8.5.1.3. Product benchmarking
- 8.5.1.4. Strategic initiatives
- 8.5.2. Lonza
- 8.5.2.1. Overview
- 8.5.2.2. Financial performance
- 8.5.2.3. Product benchmarking
- 8.5.2.4. Strategic initiatives
- 8.5.3. Fresenius Kabi AG
- 8.5.3.1. Overview
- 8.5.3.2. Financial performance
- 8.5.3.3. Product benchmarking
- 8.5.3.4. Strategic initiatives
- 8.5.4. Danaher Corporation
- 8.5.4.1. Overview
- 8.5.4.2. Financial performance
- 8.5.4.3. Product benchmarking
- 8.5.4.4. Strategic initiatives
- 8.5.5. BioSpherix, LLC
- 8.5.5.1. Overview
- 8.5.5.2. Financial performance
- 8.5.5.3. Product benchmarking
- 8.5.5.4. Strategic initiatives
- 8.5.6. Terumo Corporation
- 8.5.6.1. Overview
- 8.5.6.2. Financial performance
- 8.5.6.3. Product benchmarking
- 8.5.6.4. Strategic initiatives
- 8.5.7. Sartorius AG
- 8.5.7.1. Overview
- 8.5.7.2. Financial performance
- 8.5.7.3. Product benchmarking
- 8.5.7.4. Strategic initiatives
- 8.5.8. ThermoGenesis Holdings, Inc.
- 8.5.8.1. Overview
- 8.5.8.2. Financial performance
- 8.5.8.3. Product benchmarking
- 8.5.8.4. Strategic initiatives
- 8.5.9. CELLARES
- 8.5.9.1. Overview
- 8.5.9.2. Financial performance
- 8.5.9.3. Product benchmarking
- 8.5.9.4. Strategic initiatives
- 8.5.10. Thermo Fisher Scientific Inc.
- 8.5.10.1. Overview
- 8.5.10.2. Financial performance
- 8.5.10.3. Product benchmarking
- 8.5.10.4. Strategic initiatives